CRISPR THERAPTC (NASDAQ:CRSP) Director Kurt Von Emster sold 88,011 shares of CRISPR THERAPTC stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $19.79, for a total transaction of $1,741,737.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, August 25th, Kurt Von Emster sold 22,781 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $19.42, for a total transaction of $442,407.02.
  • On Wednesday, August 23rd, Kurt Von Emster sold 17,989 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $18.53, for a total transaction of $333,336.17.
  • On Monday, August 21st, Kurt Von Emster sold 3,150 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $18.52, for a total transaction of $58,338.00.
  • On Thursday, August 17th, Kurt Von Emster sold 34,141 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $19.06, for a total transaction of $650,727.46.
  • On Tuesday, August 15th, Kurt Von Emster sold 55,569 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $19.59, for a total transaction of $1,088,596.71.
  • On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $18.63, for a total transaction of $660,861.99.
  • On Friday, August 4th, Kurt Von Emster sold 50,477 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.81, for a total transaction of $898,995.37.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.51, for a total transaction of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.63, for a total transaction of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.60, for a total transaction of $579,568.00.

CRISPR THERAPTC (NASDAQ CRSP) opened at 20.56 on Friday. CRISPR THERAPTC has a 52-week low of $11.63 and a 52-week high of $25.00. The firm’s market capitalization is $834.55 million. The company’s 50-day moving average is $18.27 and its 200-day moving average is $17.77.

CRISPR THERAPTC (NASDAQ:CRSP) last announced its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.06. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.29 million. CRISPR THERAPTC had a negative net margin of 406.61% and a negative return on equity of 47.46%. CRISPR THERAPTC’s quarterly revenue was up 350.0% compared to the same quarter last year. Analysts forecast that CRISPR THERAPTC will post ($2.43) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/02/insider-selling-crispr-theraptc-crsp-director-sells-1741737-69-in-stock.html.

Several equities analysts have recently commented on CRSP shares. Chardan Capital restated a “buy” rating on shares of CRISPR THERAPTC in a research report on Monday, August 14th. SunTrust Banks, Inc. started coverage on shares of CRISPR THERAPTC in a research report on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a research report on Tuesday, July 18th. Finally, Cann initiated coverage on shares of CRISPR THERAPTC in a research report on Monday, July 17th. They set a “market perform” rating for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. CRISPR THERAPTC presently has a consensus rating of “Buy” and an average price target of $21.92.

A number of large investors have recently made changes to their positions in CRSP. Wellington Management Group LLP increased its stake in shares of CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares in the last quarter. IHT Wealth Management LLC bought a new stake in shares of CRISPR THERAPTC during the first quarter worth $110,000. Wells Fargo & Company MN increased its stake in shares of CRISPR THERAPTC by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC bought a new stake in shares of CRISPR THERAPTC during the second quarter worth $206,000. Finally, Monashee Investment Management LLC increased its stake in shares of CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares in the last quarter. 23.90% of the stock is currently owned by institutional investors and hedge funds.

CRISPR THERAPTC Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for CRISPR THERAPTC (NASDAQ:CRSP)

Receive News & Stock Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related stocks with our FREE daily email newsletter.